GSK Upbeat On RSV Vaccines, Hepatitis B Therapy
Walmsley Flags Future Growth Drivers
GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.
You may also be interested in...
Partnerships between big pharma and biotech focused on biologic therapies for hepatitis B could reap the benefit of less competition as lone biotechs, such as Aligos, discontinue their candidates.
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.
The European Commission’s approval of GlaxoSmithKline’s Blenrep is one of the first major fruits of a refocused pipeline and development strategy at the big pharma company.